Desert King
  • Nosotros
  • Materias Primas
    • Administración de Materias Primas: Quillaja
    • Administración de Materias Primas: Yucca
    • Administración de Materias Primas: Jojoba
  • Líneas de Negocio
    • Farmacéutica
    • Nutrición y Salud Animal
    • Alimentación y Bebidas
    • Cuidado Personal y Cosmética
    • Agricultura
    • Medio ambiente y minería
  • Calidad
  • Noticias
  • Canal de Denuncias
  • Contacto
  • Inglés
  • Español
La Opción Natural La Opción Natural La Opción Natural La Opción Natural
  • Nosotros
  • Materias Primas
    • Administración de Materias Primas: Quillaja
    • Administración de Materias Primas: Yucca
    • Administración de Materias Primas: Jojoba
  • Líneas de Negocio
    • Farmacéutica
    • Nutrición y Salud Animal
    • Alimentación y Bebidas
    • Cuidado Personal y Cosmética
    • Agricultura
    • Medio ambiente y minería
  • Calidad
  • Noticias
  • Canal de Denuncias
  • Contacto
  • Inglés
  • Español

Archives

 Zhang, Y., et al. CD25+ cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice. Virology, 2026 Aug, 621:110938. PMID: 42107283
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Zhang, Y., et al. CD25+ cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice. Virology, 2026 Aug, 621:110938. PMID: 42107283

This paper highlights the synergistic potential of combining saponin-based ISCOM adjuvants with immune regulatory modulation, specifically transient depletion of CD25+ regulatory T cells, to [...]

READ MORE
 Pyles, K., et al. Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice. NPJ Vaccines, 2026 Jul 10. PMID: 42431930
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Pyles, K., et al. Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice. NPJ Vaccines, 2026 Jul 10. PMID: 42431930

This study evaluates the immunogenicity and protective efficacy of a recombinant H5 hemagglutinin (HA) nanoparticle vaccine adjuvanted with Matrix-M, administered either intranasally or [...]

READ MORE
 Haupt, S., et al.  Rapid boosting increases germinal center responses to sequential vaccines. Nat Immunol, 2026 Jul, 27(7):1476-1489. PMID: 42337116
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Haupt, S., et al. Rapid boosting increases germinal center responses to sequential vaccines. Nat Immunol, 2026 Jul, 27(7):1476-1489. PMID: 42337116

This paper explores how rapid boosting strategies can significantly enhance germinal center (GC) responses in the context of HIV vaccination, particularly emphasizing the role of saponin-based [...]

READ MORE
 Kilic, G., et al. Age-related differences in immune responses to inactivated influenza and adjuvanted recombinant herpes zoster vaccines. JCI Insight, 2026 Jun 2. PMID: 42228420
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Kilic, G., et al. Age-related differences in immune responses to inactivated influenza and adjuvanted recombinant herpes zoster vaccines. JCI Insight, 2026 Jun 2. PMID: 42228420

This paper uniquely explores how the adjuvant AS01 enhances immune responses in aged populations, focusing on its role in overcoming immunosenescence. By comparing responses to the herpes zoster [...]

READ MORE
 Dagnew, A.F., et al. Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine. Vaccine, 2026 Jul 11, 85:128690. PMID: 42119392
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Dagnew, A.F., et al. Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine. Vaccine, 2026 Jul 11, 85:128690. PMID: 42119392

This paper presents the design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine, which incorporates the AS01 adjuvant system. The primary focus [...]

READ MORE
 Zarrinpanah, T., et al. Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology. Hum Vaccin Immunother, 2026 Dec, 22(1):2684345. PMID: 42405958
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Zarrinpanah, T., et al. Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology. Hum Vaccin Immunother, 2026 Dec, 22(1):2684345. PMID: 42405958

This paper offers a comprehensive overview of next-generation vaccine adjuvants, with particular emphasis on nanotechnology, systems immunology, and computational approaches. The review [...]

READ MORE
 Bogoyavlenskiy, A., et al. Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures. Molecules, 2026 Jul 17, 31(14):2501. PMID: 42513179
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Bogoyavlenskiy, A., et al. Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures. Molecules, 2026 Jul 17, 31(14):2501. PMID: 42513179

This paper provides a comprehensive overview of advanced nanoparticle-based vaccine platforms, including a focused emphasis on saponin-derived self-assembling nanoplatforms such as ISCOMs and [...]

READ MORE
 Jansen, J., et al. Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PLoS One, 2026 Jul 20, 21(7):e0348959. PMID: 42475333
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

Jansen, J., et al. Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PLoS One, 2026 Jul 20, 21(7):e0348959. PMID: 42475333

This paper is a significant contribution to the field of saponin-based adjuvants, particularly highlighting the potent immunostimulatory capacity of the saponin-MPLA nanoparticle adjuvant (SMNP) [...]

READ MORE
 King, H.A.D., et al. Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates. J Virol, 2026 Jul 27, e0038926. PMID: 42505121
0
By Matias Bobadilla
In Texto Cientifico
Posted 14 de agosto de 2026

King, H.A.D., et al. Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates. J Virol, 2026 Jul 27, e0038926. PMID: 42505121

This paper presents a comprehensive evaluation of the next-generation liposomal saponin-based adjuvant, ALFQ, in a primate model of HIV-1 vaccination, highlighting its capacity to elicit rapid, [...]

READ MORE

DESERT KING INTERNATIONAL
745 Main Street-
Chula Vista, CA, USA, 91911
+1 619 429 5222
info@desertking.com

DESERT KING CHILE
Avenida Industrial 1970
Quilpué, Chile, 2420505
+56 32 292 5020
info@desertking.cl

DESERT KING MEXICO
Camino Vecinal 11500-A
Tijuana B.C., México, 22664
+52 664 636 11 24
info@desertkingmexico.com

Politica de Privacidad
© 2025 Desert King. All Right Reserved

Start typing and press Enter to search